Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report) were down 7% during trading on Tuesday . The stock traded as low as $0.51 and last traded at $0.51. Approximately 130 shares traded hands during trading, a decline of 94% from the average daily volume of 2,115 shares. The stock had previously closed at $0.55.
Zelira Therapeutics Stock Performance
The business’s 50 day moving average is $0.47 and its two-hundred day moving average is $0.43.
Zelira Therapeutics Company Profile
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.
Recommended Stories
- Five stocks we like better than Zelira Therapeutics
- The 3 Best Fintech Stocks to Buy Now
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- EV Stocks and How to Profit from Them
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Zelira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zelira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
